Phaseline

Companies › DalCor Pharmaceuticals

DalCor Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Cardiovascular; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Dalcetrapib
Cholesteryl ester transfer protein inhibitor
CETPPhase 3Acute Coronary SyndromeAug 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05918861DalcetrapibPhase 3Acute Coronary SyndromeCardiovascularAug 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

CETP (1)

Companies with the same targets

NewAmsterdam Pharma

Companies built like this

Trust Bio-sonics Liquidia Technologies EVD Pharmacy and Medical Company Pulmovant EBI Anti Sepsis

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.